|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To analyze the reliability and the effectiveness of chemotherapy and prognostic factors for survival in patients with HER2 (human epidermal growth receptor 2) negative early-stage breast cancer treated with adjuvant sequential anthracycline-based chemotherapy and paclitaxel.
|
31424664 |
2020 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated adherence of human epidermal growth factor receptor-2 testing using immunohistochemistry and fluorescence in situ hybridization, as well as adjuvant trastuzumab treatment according to Canadian guidelines, and predictors of trastuzumab use in early-stage breast cancer in Ontario.
|
31156051 |
2020 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of adjuvant pertuzumab in HER2-positive early-stage breast cancer has recently been approved by the EMA on the basis of data from the APHINITY trial.
|
31830538 |
2020 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HERA trial is a phase III randomized clinical trial that established the efficacy of trastuzumab in HER-2 positive early stage breast cancer.
|
31654782 |
2020 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Electrochemical aptasensor for the detection of HER2 in human serum to assist in the diagnosis of early stage breast cancer.
|
31384983 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
|
30689703 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed an economic evaluation to assess the cost-effectiveness and budget impact of adjuvant trastuzumab therapy for HER2-positive EBC in the Philippines, using healthcare system and societal perspectives, in aid of guiding coverage decisions.
|
31752849 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 21-gene recurrence score (RS) predicts the prognosis of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and the effectiveness of adding adjuvant chemotherapy on the basis of endocrine therapy to avoid excessive chemotherapy.
|
31186766 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods</b>: Systematic search was performed through Pubmed and Scopus to identify studies comparing survival outcomes and risks of heart toxicity effects of adjuvant trastuzumab with chemotherapy versus chemotherapy alone for HER2-positive EBC patients.
|
31287333 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RT could offer significant survival benefit in luminal-A, luminal-B, and especially HER2-enriched young early-stage breast cancer female patients.
|
31016890 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One hundred thirty-eight (138) patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC who were previously tested with ODx were included for testing with the RI-DR.
|
31287883 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adjuvant CT-P6 demonstrated comparable efficacy and safety to trastuzumab at 1 year in patients with HER2-positive EBC, supporting CT-P6 and trastuzumab comparability.
|
31428820 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
|
29280043 |
2018 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The monoclonal antibody trastuzumab has improved the median disease free and overall survival of patients with early stage breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2).
|
29183167 |
2018 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to analyze how HR and HER2 receptor status have influenced the surgical management trends among patients with early stage breast cancer.
|
28811185 |
2018 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neratinib for the treatment of HER2-positive early stage breast cancer.
|
28649882 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies have recommended a 21-gene recurrence score (RS) to optimize adjuvant treatment for patients with early-stage breast cancer (EBC) with hormone receptor-positive (HR<sup>+</sup>) and human epidermal growth factor receptor-2 negative (HER2<sup>-</sup>) tumors.
|
28739750 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.
|
28744140 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly.
|
27875517 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both EBC and MBC patients can benefit from trastuzumab, as the survival data show; however, when trastuzumab is adequate in the early stage, a further trastuzumab-based therapy in first-line treatment of MBC will be ineffective, especially for those with short disease-free survival, and a second line of anti-HER2 therapy will be recommended.(Research number: CSCO-BC RWS 15001).
|
28798274 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systemic therapy for HER2-positive early-stage breast cancer.
|
27816189 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neratinib is approved in the USA for the extended adjuvant treatment of patients with HER2+ early-stage breast cancer who have been previously treated with a trastuzumab-based adjuvant regimen, and is in the preregistration phase for this indication in the EU.
|
28884417 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer.
|
28592386 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
|
28167568 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer.
|
29072977 |
2017 |